CDs with KRASG12C cooperatively sustain downstream signaling outputs to promote survival and proliferation. CDs with KRASG12C cooperatively sustain downstream.

Slides:

Advertisements

Similar presentations

Modulation of KRASG12C activity alters ARS-853 target engagement and supports novel therapeutic strategies for targeting KRAS. A, schematic for altering.

Advertisements

Drug network derived from the core EGFR interactome and combination strategy to overcome the resistant cells. Drug network derived from the core EGFR interactome.

Cytotoxicity of MSP samples to normal and cancer cell lines.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Three different types of transfer functions with a codomain of [0,1].

Human PBMC-derived MERS-CoV–specific T cells are multifunctional.

Chloroquine (CQ) improves tumor cell kill when used in combination with vemurafenib and chemotherapy in BRAFV600E-mutant cells. Chloroquine (CQ) improves.

A novice user executing various subtasks from study 1.

Tukey boxplots overlaid on data points from objective and subjective measures, displaying results from study 1. Tukey boxplots overlaid on data points.

DC subset cooperation for activation of antiviral T cells.

Characterization of the light-responsive transdermal MNs.

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Erythroid differentiation of human CD34+ cells promoted by AVP

Mammary cell proliferation is inhibited when LAD1 is depleted.

Immune cell recruitment after the NIR-boosted and MN-mediated cancer immunotherapy. Immune cell recruitment after the NIR-boosted and MN-mediated cancer.

NCMs regulate T cell survival in TLOs via PD-L1.

AMPK-mediated mTORC2 signaling does not require mTOR Ser1261phosphorylation. AMPK-mediated mTORC2 signaling does not require mTOR Ser1261phosphorylation.

Inhibiting or altering the timing of microbial antigen encounter results in inflammatory T cell responses against gut bacteria. Inhibiting or altering.

Online verification using reachable occupancies.

AMPK directly increases mTORC2 catalytic activity.

Aggregation kinetics of Aβ16–22 are unaffected by the presence of Aβ40

Antitumor effect of local cancer immunotherapy treatment in various tumor models. Antitumor effect of local cancer immunotherapy treatment in various tumor.

LIMK1 inhibition protects against Aβ-induced neuronal hyperexcitability. LIMK1 inhibition protects against Aβ-induced neuronal hyperexcitability. (A) Representative.

Fig. 2 Boronic acid–rich dendrimer in cytosolic delivery.

Fig. 2 AcPGP induces IL-8 and G-CSF release from human bronchial epithelial cells. AcPGP induces IL-8 and G-CSF release from human bronchial epithelial.

Cell viability tests. Cell viability tests. SEM images of (A) MC3T3-E1 cells and (B) MSCs on days 1, 3, and 5 of culture. (C) Survival rates of MC3T3-E1.

Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. (A)

Microrobots with different cell-carrying capacities under different grid lengths (lg) and burr lengths (lb). Microrobots with different cell-carrying capacities.

Fig. 4 Resynthesized complex boronic acid derivatives based on different scaffolds on a millimole scale and corresponding yields. Resynthesized complex.

Fig. 1 meR marks on E2F1 confer genome-wide effects.

Fig. 1 Mean and median RCR (Relative Citation Ratio) of Roadmap Epigenomics Program research articles for each year. Mean and median RCR (Relative Citation.

Inhibition of CDK9 by UNC drives MYC loss.

Slc7a5 deficiency stimulates osteoclastogenesis in vitro.

Optimization of a MYC degradation screen.

Fig. 2 CD19 CAR T cells expressing tPSMA maintain function in vitro and in vivo. CD19 CAR T cells expressing tPSMA maintain function in vitro and in vivo.

T cell–derived cytokines drive immune evasion.

A LAT-dependent amino acid uptake system operates in both osteoclasts and osteoblasts. A LAT-dependent amino acid uptake system operates in both osteoclasts.

MYC degradation screen identifies a compound that stabilizes MYC protein. MYC degradation screen identifies a compound that stabilizes MYC protein. (A)

Affinities of the SV9 specific bs-868Z11-CD3 bsTCR with different MHC monomers and peptide ligands. Affinities of the SV9 specific bs-868Z11-CD3 bsTCR.

Fig. 1. CAR4 and CAR8 cells demonstrate in vitro and in vivo antileukemic efficacy. CAR4 and CAR8 cells demonstrate in vitro and in vivo antileukemic efficacy.

Fig. 3 BMS blocks functional responses in primary immune cells driven by IL-23 and IL-12. BMS blocks functional responses in primary immune.

Fig. 5 EGLN2-mediated HIF1A down-regulation promotes ferroptosis.

BMS blocks functional responses in primary immune cells driven by IFNα

Drug response profiles and experimental validation.

Fig. 1 Bioinspired design of AAD for promoting wound contraction.

Fig. 6 SNP rs is a functional SNP in 22Rv1 cells.

In vitro cell-release experiments on a glass substrate.

Inhibiting or altering the timing of microbial antigen encounter results in inflammatory T cell responses against gut bacteria and worsened colitis upon.

Sensitivity analysis of cellular responses to perturbation of the DNA damage response signaling in the presence of chemotherapies. Sensitivity analysis.

Fig. 5 Simultaneous absence of caspase-3 and -7 is required for significant decrease of caspase-8 and -9 activation in intrinsic apoptosis. Simultaneous.

AEGIS autonomous targeting process.

Fig. 1 Synthesis and characterization of Dox-CBD-SA.

Fig. 1 Time course of growth parameters for acetate-grown cultures of M. acetivorans with and without supplements. Time course of growth parameters for.

Fig. 3 Production of protein and Fe(II) at the end of growth correlated with increasing concentrations of ferrihydrite in the media that contained 0.2.

Pharmacological targeting of CDs promotes response to KRASG12C inhibition in vivo. Pharmacological targeting of CDs promotes response to KRASG12C inhibition.

Fig. 4 Dox-CBD-SA treatment shows reduced toxicity.

Combination therapies targeting CDs with KRASG12C differ in their ability to promote S-IIP target engagement. Combination therapies targeting CDs with.

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

Fig. 1 Location of the Jirzankal Cemetery.

UNC drives MYC protein loss.

Fig. 3 Effects of ASO and eGLP1-ASO conjugates on gene expression and protein levels in vitro in cell lines and primary mouse islet cells. Effects of ASO.

Fig. 2 BX795 is nontoxic to HCE cells at therapeutic concentration.

Fig. 4 A novel peptidomimetic (AV3) against ITGA5.

Fig. 4 Behavior of resistance peak near density nm = 5.

Afatinib rapidly destabilizes endogenous TRIB2 and specifically induces caspase 3 cleavage and U937 cytotoxicity. Afatinib rapidly destabilizes endogenous.

Fig. 5 Cytosolic delivery of toxic proteins.

Fig. 1 ETL kills 4T1 breast carcinoma cells more efficiently than ST under static conditions. ETL kills 4T1 breast carcinoma cells more efficiently than.

Fig. 4 Effects of individual picosecond and microsecond pulses.

Fig. 5 Treatment with molecules 13, 14, and 15 decreases HIV-1 R5 infection in human macrophages. Treatment with molecules 13, 14, and 15 decreases HIV-1.

Fig. 5 CD19-tPSMA(N9del) CAR T cell numbers in mouse and human.

Presentation transcript:

CDs with KRASG12C cooperatively sustain downstream signaling outputs to promote survival and proliferation. CDs with KRASG12C cooperatively sustain downstream signaling outputs to promote survival and proliferation. (A) Immunoblots of H358 and MIA PaCa-2 cells treated with ARS-1323-alkyne (10 μM) simultaneously with DMSO, EGF (100 ng/ml), FGF2 (100 ng/ml), erlotinib (10 μM, EGFRi), AZD4547 (10 μM, FGFRi), bemcentinib (10 μM, AXLi), SHP099 (10 μM, SHP2i), buparlisib (10 μM, PI3Ki), or palbociclib (10 μM, CDK4/6i) for 2 hours. Lysates were subjected to copper-catalyzed click reaction with TAMRA-N3. Cells were grown in 3D spheroid culture. Immunoblots represent two biological replicates. (B) Combination indices (CIs) derived from drug synergism in three KRASG12C-mutant cell lines assessed in 3D spheroid culture. Cell viability was determined after 5-day treatment with ARS-1620, second compounds, or the combination in a 1:1 ratio (dilution series from 1.5 nM to 10 μM), and CI values were calculated using CompuSyn 1.0 from three biological replicates. CI < 0.75 indicates synergism with ARS-1620 (red), CI = 0.75 to 1.25 indicates additivity, and CI > 1.25 indicates antagonism. (C) Clonogenic assays of three KRASG12C-mutant cell lines cultured with indicated compounds or combinations thereof in 2D adherent culture. H358 (300 nM), MIA PaCa-2 (1 μM), and H23 (1 μM) cells were treated using ARS-1620 and second compounds at a 1:1 concentration. Data are representative of three biological replicates. Kevin Lou et al., Sci. Signal. 2019;12:eaaw9450 Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works